Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a mouse IgG2a Fc tag at the C-terminus
The protein has a calculated MW of 84.9 kDa. The protein migrates as 95-100 kDa under reducing (R) condition (SDS-PAGE) due to Glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD73, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human CD73, Mouse IgG2a Fc Tag (Cat. No. CD3-H5252) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD73 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).
Measured by its ability to hydrolyze the 5’-phosphate group from the substrate adenosine-5’-monophosphate (AMP). The specific activity is > 56,000 pmol/min/μg (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Uliledlimab | TJ-4309; TJ-004309; TJD-5 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis | Details |
Quemliclustat | AB-680 | Phase 3 Clinical | Arcus Biosciences Inc | Biliary Tract Neoplasms; Pancreatic Neoplasms; Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms, Castration-Resistant; Cholangiocarcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Oleclumab | MEDI-9447 | Phase 3 Clinical | Medimmune Llc | Prostatic Neoplasms, Castration-Resistant; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Osteosarcoma; Urinary Bladder Neoplasms; Solid tumours; Liposarcoma; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hemangiosarcoma; Ovarian Neoplasms | Details |
Dalutrafusp alfa | GS-1423; AGEN-1423 | Phase 2 Clinical | Agenus Inc | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
BMS-986179 | BMS-986179 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details |
Mupadolimab | CPX-006; COR-004 (Corvus Pharmaceuticals); CPI-006 | Phase 2 Clinical | Corvus Pharmaceuticals Inc | Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours | Details |
Dresbuxelimab | AK-119 | Phase 2 Clinical | Akeso Pharmaceuticals Inc | Solid tumours; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
S-095024 | S-095024; S095024 | Phase 2 Clinical | Institut De Recherches Internationales Servier, Servier Bio-Innovation LLC, Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
HB-0045 | HB-0045; HB0045 | Phase 2 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd, HuaBo Biopharm Co Ltd | Solid tumours | Details |
JAB-BX102 | JAB-BX102 | Phase 2 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details |
PT-199 | PT-199 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
LY-3475070 | LY-3475070 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details |
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details | |
Uprevstobart | INCA-00186 | Phase 1 Clinical | Incyte Corp Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Gastrointestinal Neoplasms | Details |
AK-137 | AK137; AK-137 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Neoplasms | Details |
68GA-DOTA-dPNE | 68GA-DOTA-dPNE | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
HB-0052 | HB-0052; HB0052 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
BPI-472372 | BPI-472372 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
BB-1709 | BB-1709 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours | Details |
PM-1015 | PM1015; PM-1015 | Phase 1 Clinical | Solid tumours | Details | |
AK-131 | AK-131 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
IBI-325 | IBI-325 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
BR-101 | BR101; BR-101 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
CB-708 | ATG-037; ATN-037; CB-708; CB708 | Phase 1 Clinical | Calithera Biosciences Inc | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
HLX-23 | HLX-23 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Lymphoma | Details |
ORIC533 | ORIC-533 | Phase 1 Clinical | Oric Pharmaceuticals Inc | Multiple Myeloma; Neoplasm Metastasis | Details |
IPH-5301 | IPH-5301 | Phase 1 Clinical | Innate Pharma | Solid tumours; Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Endometrial Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
HBM-1007 | HBM1007; R 1007; HBM 1007; HBM-1007 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Neoplasms | Details |
ABSK-051 | ABSK051 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.